NAYA Biosciences Inc - מכפיל EV/Sales NAYA

NAYA Biosciences develops oncology drugs through partnerships with medical centers. The GURU.Markets terminal displays an enterprise value-to-revenue chart, where the value represents the latest figure. NAYA Biosciences seeks alternatives to chemotherapy by activating NK cells. The current R&D stage precludes commercial revenue, shifting business scaling into the realm of increasing fixed costs for scientific research.
NAYA (nayabiosciences.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For NAYA Biosciences, which is developing the Flex-NK platform for targeted immunotherapy of solid tumors, the potential for technology commercialization serves as a key valuation factor. By analyzing the ratio of Enterprise Value to revenue, an investor can view the market value of the entire business, including net debt, relative to sales, which allows for an assessment of the premium for future growth and the risk of overpayment within M&A transactions.